Gilbert J Burckart1, William D Figg2, Maria M Brooks3, Dionna J Green1, Sarah M Troutman2, Robert Ferrell4, Richard Chinnock5, Charles Canter6, Linda Addonizio7, Daniel Bernstein8, James K Kirklin9, David Naftel10, Douglas K Price2, Tristan M Sissung2, Diana M Girnita10, Adriana Zeevi10, Steven A Webber11. 1. Pediatric Clinical Pharmacology Staff, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland. 2. Medical Pharmacology Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 3. Department of Epidemiology. 4. Department of Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania. 5. Department of Pediatrics, Loma Linda University, Loma Linda University Children's Hospital, Loma Linda, California. 6. Department of Pediatrics, Division of Cardiology, Washington University School of Medicine, St Louis Children's Hospital, St Louis, Missouri. 7. Department of Pediatrics, Division of Cardiology, Columbia University, New York Presbyterian Hospital, New York, New York. 8. Department of Pediatrics, Division of Cardiology, Stanford University, Lucile Packard Children's Hospital, Palo Alto, California. 9. Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama. 10. Department of Pathology, Thomas E Starzl Transplant Institute. 11. Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee.
Abstract
OBJECTIVES: Earlier studies have indicated that the pharmacokinetics of mycophenolic acid (MPA) is influenced by polymorphisms of ABCC2, which encodes for the membrane transporter MRP2. The ABCC2 rs717620 A allele has been associated with enterohepatic recirculation of MPA, and our previous work had correlated the discontinuance of MPA with this allele in pediatric heart transplant patients. Therefore, we hypothesized that the ABCC2 rs717620 A allele would be associated with poorer outcomes including rejection with hemodynamic compromise (RHC), graft failure, and death in the pediatric heart transplant (PHTx) population receiving MPA. METHODS: PHTx recipients from 6 institutions in the Pediatric Heart Transplantation Study (PHTS) from the period of 1993-2009, receiving MPA therapy, were genotyped for ABCC2 rs717620. Genotyping was accomplished by direct sequencing. Demographic and outcome data were limited to the data routinely collected as part of the PHTS and included RHC and mortality. RESULTS: Two hundred ninety patients were identified who received MPA at some point post transplantation, of which 200 carried the GG genotype, 81 carried the AG genotype, and 9 carried the AA genotype. Follow-up time after transplantation was 6 years. RHC occurred in 76 patients and 18 patients died. In the 281 patients followed up more than 1 year, late RHC (>1 year post transplantation) occurred in 42 patients. While both RHC and late RHC were associated with the ABCC2 rs717620 GG genotype (hazard ratios: 1.80 and 4.57, respectively, p<0.05) in all patients, this association was not significant in PHTx patients receiving only MPA as the antiproliferative agent from the time of transplant (n=142). CONCLUSIONS: ABCC2 rs717620 polymorphisms varied within racial groups. As a candidate gene assessment, the ABCC2 rs717620 AG and AA genotypes may be associated with improved, rather than poorer, RHC in PHTx patients receiving MPA therapy. ABCC2 rs717620 polymorphisms should be included in any expanded pharmacogenomic analysis of outcomes after pediatric heart transplantation.
OBJECTIVES: Earlier studies have indicated that the pharmacokinetics of mycophenolic acid (MPA) is influenced by polymorphisms of ABCC2, which encodes for the membrane transporter MRP2. The ABCC2rs717620 A allele has been associated with enterohepatic recirculation of MPA, and our previous work had correlated the discontinuance of MPA with this allele in pediatric heart transplant patients. Therefore, we hypothesized that the ABCC2rs717620 A allele would be associated with poorer outcomes including rejection with hemodynamic compromise (RHC), graft failure, and death in the pediatric heart transplant (PHTx) population receiving MPA. METHODS: PHTx recipients from 6 institutions in the Pediatric Heart Transplantation Study (PHTS) from the period of 1993-2009, receiving MPA therapy, were genotyped for ABCC2rs717620. Genotyping was accomplished by direct sequencing. Demographic and outcome data were limited to the data routinely collected as part of the PHTS and included RHC and mortality. RESULTS: Two hundred ninety patients were identified who received MPA at some point post transplantation, of which 200 carried the GG genotype, 81 carried the AG genotype, and 9 carried the AA genotype. Follow-up time after transplantation was 6 years. RHC occurred in 76 patients and 18 patients died. In the 281 patients followed up more than 1 year, late RHC (>1 year post transplantation) occurred in 42 patients. While both RHC and late RHC were associated with the ABCC2rs717620 GG genotype (hazard ratios: 1.80 and 4.57, respectively, p<0.05) in all patients, this association was not significant in PHTx patients receiving only MPA as the antiproliferative agent from the time of transplant (n=142). CONCLUSIONS:ABCC2rs717620 polymorphisms varied within racial groups. As a candidate gene assessment, the ABCC2rs717620 AG and AA genotypes may be associated with improved, rather than poorer, RHC in PHTx patients receiving MPA therapy. ABCC2rs717620 polymorphisms should be included in any expanded pharmacogenomic analysis of outcomes after pediatric heart transplantation.
Authors: Clifford Chin; David C Naftel; Tajinder P Singh; Elizabeth D Blume; Helen Luikart; Daniel Bernstein; Pat Gamberg; James K Kirklin; W Robert Morrow Journal: J Heart Lung Transplant Date: 2004-02 Impact factor: 10.247
Authors: Melanie D Everitt; Elfriede Pahl; Kenneth B Schechtman; Jie Zheng; Jeremy M Ringewald; Thomas L'ecuyer; David C Naftel; James K Kirklin; Elizabeth D Blume; Emily A Bullock; Charles E Canter Journal: J Heart Lung Transplant Date: 2010-10-25 Impact factor: 10.247
Authors: M Baraldo; M Isola; M T Feruglio; A Francesconi; L Franceschi; V Tursi; U Livi; M Furlanut Journal: Transplant Proc Date: 2005-06 Impact factor: 1.066
Authors: M Shipkova; V W Armstrong; D Kuypers; F Perner; V Fabrizi; H Holzer; E Wieland; M Oellerich Journal: Ther Drug Monit Date: 2001-12 Impact factor: 3.681
Authors: Daphne T Hsu; David C Naftel; Steven A Webber; William R Morrow; Charles E Canter; Richard E Chinnock; Mary Lynne Clark; James K Kirklin Journal: Congenit Heart Dis Date: 2006-05 Impact factor: 2.007
Authors: Diana M Girnita; Steven A Webber; Robert Ferrell; Gilbert J Burckart; Maria M Brooks; Kevin K McDade; Richard Chinnock; Charles Canter; Linda Addonizio; Daniel Bernstein; James K Kirklin; Alin L Girnita; Adriana Zeevi Journal: Transplantation Date: 2006-12-27 Impact factor: 4.939
Authors: Ferdi Sombogaard; Ron H N van Schaik; Ron A Mathot; Klemens Budde; Marloes van der Werf; Arnold G Vulto; Willem Weimar; Petra Glander; Laurent Essioux; Teun van Gelder Journal: Pharmacogenet Genomics Date: 2009-08 Impact factor: 2.089
Authors: Jae Wook Yang; Puay Hoon Lee; Ian V Hutchinson; Vera Pravica; Tariq Shah; David I Min Journal: Ther Drug Monit Date: 2009-10 Impact factor: 3.681
Authors: Paul J Galiwango; Diego H Delgado; Raymond Yan; Stella Kozuszko; Robert Smith; Vivek Rao; Heather J Ross Journal: J Heart Lung Transplant Date: 2008-01 Impact factor: 10.247
Authors: Jesus Ruiz; María José Herrero; Virginia Bosó; Juan Eduardo Megías; David Hervás; Jose Luis Poveda; Juan Escrivá; Amparo Pastor; Amparo Solé; Salvador Francisco Aliño Journal: Int J Mol Sci Date: 2015-08-25 Impact factor: 5.923